---
title: Innovative Two-Part Feed Boosts Titer and Consistency in CHO-K1 formAbs and mAb Variants
description: In this webinar, learn why there's a growing need for feed systems that can support mAbs and bsAbs while maintaining high titers and product quality. 
---

[![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

#                                          ![New-ATE-Logo2019 (1)](https://bpi.bioprocessintl.com/hs-fs/hubfs/New-ATE-Logo2019%20(1).png?width=700&name=New-ATE-Logo2019%20(1).png)

# Innovative Two-Part

# Feed Boosts Titer and Consistency

# in CHO-K1 for mAbs and mAb Variants

|  |
| --- |

## Presenter:

****![09-30-2025-Thermo-Fisher-ATE-Speaker-HS-Cropped](https://bpi.bioprocessintl.com/hs-fs/hubfs/09-30-2025-Thermo-Fisher-ATE-Speaker-HS-Cropped.png?width=150&height=217&name=09-30-2025-Thermo-Fisher-ATE-Speaker-HS-Cropped.png)****

**Gino Stolfa, PhD**

*Senior Staff Scientist, Cell Culture and Cell Therapy BU, Bioproduction Group,*

Thermo Fisher Scientific

 

Gino Stolfa is currently a research and development scientist at Thermo Fisher Scientific in Grand Island, NY. Stolfa earned his doctoral degree from University at Buffalo, The State University of New York in biological sciences, studying the interaction between bacteria containing toxin encoding phages and single-celled eukaryotes. His post-doctoral research focused on glycosylation of cell surface proteins involved in leukocyte homing. His current research interests involve custom media development and cell line development as well as genome editing and screening technologies.   

 

## About this event:

#### Date: September 30, 2025

#### Time: 11 am EDT | 8 am PDT | 5 pm CEST

#### Duration: 40 minutes

| As biotherapeutic pipelines increasingly include mAb variants such as bispecific antibodies (bsAbs) and FC-fusion proteins, there is a growing need for feed systems that can support these advanced modalities while maintaining high titers and product quality.  In this webinar, Thermo Fisher will describe a novel, two-part, chemically defined feed system that was developed using metabolomics, high-throughput screening (HTS), and design of experiments (DoE): Efficient-Pro™ Feed 3 and Feed Enhancer. Designed to complement the Efficient-Pro™ basal media platform, this system enables robust performance across multiple CHO-K1 GS lineages.    Key Takeaways:   - Consistent scalability  - Titer improvements in monoclonal antibody production versus internal feeds  - Support for complex molecules  - This expanded media and feed platform empowers upstream teams to achieve higher productivity, scalability, and quality across a diverse range of molecule types and CHO cell lines.  |
| --- |

 

-  

-  

©2015 BioProcess International All Rights reserved